Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICE: Certolizumab Pegol Strategies in RA
NCT02293590Phase 2Completed
- Sponsor
- RBM-Consulting
- Start
- Nov 2013
- Primary completion
- Dec 2017
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by RBM-Consulting. Started Nov 2013; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02293590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293590.